Citations

Clear

133 citation(s) found for "SCHAID, D".

Mutational landscape of candidate genes in familial prostate cancer
Johnson, Anna , Zuhlke, Kimberly A. , Plotts, Chris, McDonnell, Shannon K. , Middha, Sumit , Riska, Shaun M., Schaid, Daniel J. , Thibodeau, Stephen N. , Douglas, Julie A. , Cooney, Kathleen A. , McDonnell, Shannon K

Mayo Clinic

The Prostate | August 11, 2014 | Volume: 74 | Issue: 14 | Pages: 1371-1378

10.1002/pros.22849 | PMID 25111073 Get It

PedBLIMP: Extending Linear Predictors to Impute Genotypes in Pedigrees
Chen, Wenan , Schaid, Daniel J.

Mayo Clinic

Genetic Epidemiology | July 15, 2014 | Volume: 38 | Issue: 6 | Pages: 531-541

10.1002/gepi.21838 | PMID 25044249 Get It

Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury
Schaid, Daniel J. , Spraggs, Colin F., McDonnell, Shannon K. , Parham, Laura R. , Cox, Charles, Ejlertsen, Bent , Rappold, Erica, Curran, Joan, Cardon, Lon R., Goss, Paul E. , Cox, Charles J, Finkelstein, Dianne M, Finkelstein, Dianne M. , McDonnell, Shannon K

Mayo Clinic

Journal of Clinical Oncology | April 1, 2014 | Volume: 32 | Issue: 22 | Pages: 2296-2303

10.1200/jco.2013.52.9867 | PMID 24687830 Get It

Purpose Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously associated major histocompatibility complex (MHC) variants as predictors of risk of liver injury by using a large, randomized, placebo-controlled trial of lapatinib in human epidermal growth factor receptor 2–positive, early-stage breast cancer (Tykerb Evaluation After Chemotherapy [TEACH]: Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer). Patients and Methods The frequency of ALT elevation cases was compared among four MHC variants in 1,194 patients randomly assigned to lapatinib. Cumulative ALT elevation time courses during treatment were also compared between carriers and noncarriers of specified MHC variants. Results In lapatinib-treated patients, there was a significant difference in ALT case incidence between HLA carriers and noncarriers. The highly correlated alleles HLA-DRB1*07:01 and HLA-DQA1*02:01 (study frequency, 22.4%) were associated with ALT elevation (odds ratio, 14) between cases (n = 37) and controls (n = 1,071). These associations strengthened at higher ALT elevation thresholds and in Hy's Law cases. In lapatinib-treated patients, the overall risk for National Cancer Institute-Common Terminology Criteria for Adverse Events grade 3 ALT elevation (> 5× upper limit of normal) was 2.1%; HLA allele carriers had an increased risk of 7.7%; in noncarriers, risk was reduced to 0.5%, comparable to ALT elevation for all patients receiving placebo. The increase in ALT case incidence in the lapatinib arm showed no evidence of plateau during 1 year of lapatinib treatment. Conclusion These results validate HLA-DRB1*07:01 allele carriage as a predictor of increased risk of lapatinib-induced liver injury and implicate an immune pathology. The HLA association could support clinical management of patients experiencing hepatotoxicity during lapatinib treatment.
Citalopram and escitalopram plasma drug and metabolite concentrations: genome‐wide associations
Schaid, Daniel J. , Desta, Zeruesenay , Kubo, Michiaki , Batzler, Anthony , Snyder, Karen, Ogburn, Evan T., Hall‐Flavin, Daniel K., Flockhart, David A., Nakamura, Yusuke , Mrazek, David A. , Weinshilboum, Richard M. , Ji, Yuan , Mushiroda, Taisei , Kamatani, Naoyuki , Weinshilboum, Richard M.

Mayo Clinic

British Journal of Clinical Pharmacology | February 17, 2014 | Volume: 78 | Issue: 2 | Pages: 373-383

10.1111/bcp.12348 | PMID 24528284 Get It

Aims Citalopram ( CT ) and escitalopram ( S ‐ CT ) are among the most widely prescribed selective serotonin reuptake inhibitors used to treat major depressive disorder ( MDD ). We applied a genome‐wide association study to identify genetic factors that contribute to variation in plasma concentrations of CT or S ‐ CT and their metabolites in MDD patients treated with CT or S ‐ CT . Methods Our genome‐wide association study was performed using samples from 435 MDD patients. Linear mixed models were used to account for within‐subject correlations of longitudinal measures of plasma drug/metabolite concentrations (4 and 8 weeks after the initiation of drug therapy), and single‐nucleotide polymorphisms ( SNPs ) were modelled as additive allelic effects. Results Genome‐wide significant associations were observed for S ‐ CT concentration with SNPs in or near the CYP2C19 gene on chromosome 10 (rs1074145, P = 4.1 × 10 −9 ) and with S ‐didesmethylcitalopram concentration for SNPs near the CYP2D6 locus on chromosome 22 (rs1065852, P = 2.0 × 10 −16 ), supporting the important role of these cytochrome P450 ( CYP ) enzymes in biotransformation of citalopram. After adjustment for the effect of CYP2C19 functional alleles, the analyses also identified novel loci that will require future replication and functional validation. Conclusions In vitro and in vivo studies have suggested that the biotransformation of CT to monodesmethylcitalopram and didesmethylcitalopram is mediated by CYP isozymes. The results of our genome‐wide association study performed in MDD patients treated with CT or S ‐ CT have confirmed those observations but also identified novel genomic loci that might play a role in variation in plasma levels of CT or its metabolites during the treatment of MDD patients with these selective serotonin reuptake inhibitors.
Regularized Rare Variant Enrichment Analysis for Case‐Control Exome Sequencing Data
Schaid, Daniel J. , Larson, Nicholas B.

Mayo Clinic

Genetic Epidemiology | December 30, 2013 | Volume: 38 | Issue: 2 | Pages: 104-113

10.1002/gepi.21783 | PMID 24382715 Get It

ABSTRACTRare variants have recently garnered an immense amount of attention in genetic association analysis. However, unlike methods traditionally used for single marker analysis in GWAS, rare variant analysis often requires some method of aggregation, since single marker approaches are poorly powered for typical sequencing study sample sizes. Advancements in sequencing technologies have rendered next‐generation sequencing platforms a realistic alternative to traditional genotyping arrays. Exome sequencing in particular not only provides base‐level resolution of genetic coding regions, but also a natural paradigm for aggregation via genes and exons. Here, we propose the use of penalized regression in combination with variant aggregation measures to identify rare variant enrichment in exome sequencing data. In contrast to marginal gene‐level testing, we simultaneously evaluate the effects of rare variants in multiple genes, focusing on gene‐based least absolute shrinkage and selection operator (LASSO) and exon‐based sparse group LASSO models. By using gene membership as a grouping variable, the sparse group LASSO can be used as a gene‐centric analysis of rare variants while also providing a penalized approach toward identifying specific regions of interest. We apply extensive simulations to evaluate the performance of these approaches with respect to specificity and sensitivity, comparing these results to multiple competing marginal testing methods. Finally, we discuss our findings and outline future research.
A Kernel Regression Approach to Gene‐Gene Interaction Detection for Case‐Control Studies
Schaid, Daniel J. , Larson, Nicholas B.

Mayo Clinic

Genetic Epidemiology | July 19, 2013 | Volume: 37 | Issue: 7 | Pages: 695-703

10.1002/gepi.21749 | PMID 23868214 Get It

ABSTRACTGene‐gene interactions are increasingly being addressed as a potentially important contributor to the variability of complex traits. Consequently, attentions have moved beyond single locus analysis of association to more complex genetic models. Although several single‐marker approaches toward interaction analysis have been developed, such methods suffer from very high testing dimensionality and do not take advantage of existing information, notably the definition of genes as functional units. Here, we propose a comprehensive family of gene‐level score tests for identifying genetic elements of disease risk, in particular pairwise gene‐gene interactions. Using kernel machine methods, we devise score‐based variance component tests under a generalized linear mixed model framework. We conducted simulations based upon coalescent genetic models to evaluate the performance of our approach under a variety of disease models. These simulations indicate that our methods are generally higher powered than alternative gene‐level approaches and at worst competitive with exhaustive SNP‐level (where SNP is single‐nucleotide polymorphism) analyses. Furthermore, we observe that simulated epistatic effects resulted in significant marginal testing results for the involved genes regardless of whether or not true main effects were present. We detail the benefits of our methods and discuss potential genome‐wide analysis strategies for gene‐gene interaction analysis in a case‐control study design.
Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
Liu, Mohan , Wickerham, D. Lawrence, Schaid, Daniel J. , Wang, Liewei , Kubo, Michiaki , Costantino, Joseph P., Vogel, Victor G. , Paik, Soonmyung , Ames, Matthew M. , Jenkins, Gregory D. , Batzler, Anthony , Flockhart, David A., Nakamura, Yusuke , Weinshilboum, Richard M. , Ingle, James N. , Mushiroda, Taisei , Goetz, Matthew P. , Carlson, Erin E. , Wolmark, Norman , Weinshilboum, Richard M.

Mayo Clinic

Cancer Discovery | June 14, 2013 | Volume: 3 | Issue: 7 | Pages: 812-825

10.1158/2159-8290.cd-13-0038 | PMID 23764426 Get It

Abstract The selective estrogen receptor modulators (SERM) tamoxifen and raloxifene can reduce the occurrence of breast cancer in high-risk women by 50%, but this U.S. Food and Drug Administration-approved prevention therapy is not often used. We attempted to identify genetic factors that contribute to variation in SERM breast cancer prevention, using DNA from the NSABP P-1 and P-2 breast cancer prevention trials. An initial discovery genome-wide association study identified common single-nucleotide polymorphisms (SNP) in or near the ZNF423 and CTSO genes that were associated with breast cancer risk during SERM therapy. We then showed that both ZNF423 and CTSO participated in the estrogen-dependent induction of BRCA1 expression, in both cases with SNP-dependent variation in induction. ZNF423 appeared to be an estrogen-inducible BRCA1 transcription factor. The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5.71. Significance: This study identified novel, functionally polymorphic genes involved in the estrogen-dependent regulation of BRCA1 expression, as well as a novel mechanism for genetic variation in SERM therapeutic effect. These observations, and definition of their underlying mechanisms, represent steps toward pharmacogenomically individualized SERM breast cancer prevention. Cancer Discov; 3(7); 812–25. ©2013 AACR. See related commentary by Machiela and Chanock, p. 728 This article is highlighted in the In This Issue feature, p. 705
Multiple Genetic Variant Association Testing by Collapsing and Kernel Methods With Pedigree or Population Structured Data
Schaid, Daniel J. , McDonnell, Shannon K. , Sinnwell, Jason P. , Thibodeau, Stephen N. , Sinnwell, Jason P , McDonnell, Shannon K

Mayo Clinic

Genetic Epidemiology | May 5, 2013 | Volume: 37 | Issue: 5 | Pages: 409-418

10.1002/gepi.21727 | PMID 23650101 Get It

ABSTRACTSearching for rare genetic variants associated with complex diseases can be facilitated by enriching for diseased carriers of rare variants by sampling cases from pedigrees enriched for disease, possibly with related or unrelated controls. This strategy, however, complicates analyses because of shared genetic ancestry, as well as linkage disequilibrium among genetic markers. To overcome these problems, we developed broad classes of “burden” statistics and kernel statistics, extending commonly used methods for unrelated case‐control data to allow for known pedigree relationships, for autosomes and the X chromosome. Furthermore, by replacing pedigree‐based genetic correlation matrices with estimates of genetic relationships based on large‐scale genomic data, our methods can be used to account for population‐structured data. By simulations, we show that the type I error rates of our developed methods are near the asymptotic nominal levels, allowing rapid computation of P‐values. Our simulations also show that a linear weighted kernel statistic is generally more powerful than a weighted “burden” statistic. Because the proposed statistics are rapid to compute, they can be readily used for large‐scale screening of the association of genomic sequence data with disease status.